THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors
14 août 2024 07h30 HE | Abeona Therapeutics Inc.
CLEVELAND, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Bernhardt G. Zeiher, MD, FCCP, FACP, and Eric Crombez, MD as new independent...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel
13 août 2024 07h30 HE | Abeona Therapeutics Inc.
CLEVELAND, Ohio, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the Centers for Medicare and Medicaid Services (CMS) has granted a product-specific...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission
12 août 2024 07h30 HE | Abeona Therapeutics Inc.
Significant progress addressing CMC items noted in CRL BLA resubmission remains on track for 2H 2024 CLEVELAND, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 août 2024 07h30 HE | Abeona Therapeutics Inc.
CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications
11 juil. 2024 07h30 HE | Abeona Therapeutics Inc.
CLEVELAND and LONDON, July 11, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a cell and gene therapy company with proprietary adeno-associated virus (AAV)-based capsids, and...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum
08 juil. 2024 07h30 HE | Abeona Therapeutics Inc.
CLEVELAND, July 08, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Abeona’s Chief Executive Officer, Vish Seshadri, Ph.D., M.B.A., and Chief Commercial...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 juin 2024 07h30 HE | Abeona Therapeutics Inc.
CLEVELAND, June 03, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference
28 mai 2024 07h30 HE | Abeona Therapeutics Inc.
CLEVELAND, May 28, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its senior management team will participate in a fireside chat at the Jefferies...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress
15 mai 2024 07h30 HE | Abeona Therapeutics Inc.
BLA resubmission anticipated in second half of 2024 Closed $75 million underwritten offering in May, extending expected cash runway into 2026 CLEVELAND, May 15, 2024 (GLOBE NEWSWIRE) -- Abeona...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 mai 2024 07h30 HE | Abeona Therapeutics Inc.
CLEVELAND, May 07, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity...